Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. Branford S, et al. Among authors: hughes tp. Blood. 2002 May 1;99(9):3472-5. doi: 10.1182/blood.v99.9.3472. Blood. 2002. PMID: 11964322 Free article.
Imatinib as a potential antiresorptive therapy for bone disease.
Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC. Dewar AL, et al. Among authors: hughes tp. Blood. 2006 Jun 1;107(11):4334-7. doi: 10.1182/blood-2005-09-3568. Epub 2006 Jan 31. Blood. 2006. PMID: 16449525 Free article.
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. White DL, et al. Among authors: hughes tp. Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4. Blood. 2006. PMID: 16597591 Free article.
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Hochhaus A, et al. Among authors: hughes tp. Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30. Blood. 2007. PMID: 17138817 Free article. Clinical Trial.
Long-term imatinib therapy promotes bone formation in CML patients.
Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Fitter S, et al. Among authors: hughes tp. Blood. 2008 Mar 1;111(5):2538-47. doi: 10.1182/blood-2007-07-104281. Epub 2007 Nov 27. Blood. 2008. PMID: 18042796 Free article.
374 results